Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 253-263 , June 2008

Physiology of the vasopressin receptors

  • Marc O. Maybauer, MD, PhD (Assistant Professor in Anesthesiology)
    • ,
  • Dirk M. Maybauer, MD, PhD (Assistant Professor in Anesthesiology)
    • ,
  • Perenlei Enkhbaatar, MD, PhD (Associate Professor of Anesthesiology Associate Director in The Investigative Intensive Care Unit)
    • ,
  • Daniel L. Traber, PhD, FCCM (Charles Robert Allen Professor of Anesthesiology Director in The Investigative Intensive Care Unit Professor of Neuroscience and Cell Biology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 409 772 6405; Fax: +1 409 772 6409.

References 

  1. Oliver G, Schafer EA. On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication. The Journal of Physiology. 1895;18(3):277–279
  2. Du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. The Journal of Biological Chemistry. 1953;205(2):949–957
  3. Caldwell HK, Young WS. Oxytocin and vasopressin: genetics and behavioral implications. In:  Lim R editors. Handbook of neurochemistry and molecular neurobiology: neuroactive proteins and peptides. 3rd ed.. New York: Springer; 2006;p. 573–607
  4. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. The Journal of Endocrinology. 1998;156(2):223–229
  5. Riddell DC, Mallonee R, Phillips JA, et al. Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somatic Cell and Molecular Genetics. 1985;11(2):189–195
  6. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 2-clinical physiology. Critical Care (London, England). 2004;8(1):15–23
  7. Ertmer C, Bone HG, Morelli A, et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock (Augusta, Ga.). 2007;27(3):281–288
  8. Bassi G, Radermacher P, Calzia E. Catecholamines and vasopressin during critical illness. Endocrinology and Metabolism Clinics of North America. 2006;35(4):839–857x
  9. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1–receptor physiology. Critical Care (London, England). 2003;7(6):427–434
  10. Thibonnier M, Graves MK, Wagner MS, et al. Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene. Genomics. 1996;31(3):327–334
  11. Lange M, Ertmer C, Westphal M. Vasopressin vs. terlipressinin the treatmentof cardiovascular failure in sepsis. Intensive Care Medicine. 2007;
  12. Johnston CI. Vasopressin in circulatory control and hypertension. Journal of Hypertension. 1985;3(6):557–569
  13. Abboud FM, Floras JS, Aylward PE, et al. Role of vasopressin in cardiovascular and blood pressure regulation. Blood Vessels. 1990;27(2–5):106–115
  14. Bishop VS, Hay M. Involvement of the area postrema in the regulation of sympathetic outflow to the cardiovascular system. Frontiers in Neuroendocrinology. 1993;14(2):57–75
  15. Aki Y, Tamaki T, Kiyomoto H, et al. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation. Journal of Cardiovascular Pharmacology. 1994;23(2):331–336
  16. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovascular Research. 2001;51(3):372–390
  17. Tahara A, Saito M, Tsukada J, et al. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. European Journal of Pharmacology. 1999;368(1):89–94
  18. Birnbaumer M, Seibold A, Gilbert S, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992;357(6376):333–335
  19. Seibold A, Brabet P, Rosenthal W, et al. Structure and chromosomal localization of the human antidiuretic hormone receptor gene. American Journal of Human Genetics. 1992;51(5):1078–1083
  20. Nielsen S, Frokiaer J, Marples D, et al. Aquaporins in the kidney: from molecules to medicine. Physiological Reviews. 2002;82(1):205–244
  21. Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science. 1994;264(5155):92–95
  22. Sasaki S, Fushimi K, Saito H, et al. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. The Journal of Clinical Investigation. 1994;93(3):1250–1256
  23. Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. Journal of the American Society of Nephrology: JASN. 2005;16(10):2836–2846
  24. Saito M, Tahara A, Sugimoto T, et al. Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor. European Journal of Pharmacology. 2000;401(3):289–296
  25. Bichet DG, Razi M, Lonergan M, et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. The New England Journal of Medicine. 1988;318(14):881–887
  26. Thibonnier M, Preston JA, Dulin N, et al. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997;138(10):4109–4122
  27. Rousseau-Merck MF, Rene P, Derre J, et al. Chromosomal localization of the human V3 pituitary vasopressin receptor gene (AVPR3) to 1q32. Genomics. 1995;30(2):405–406
  28. Lee B, Yang C, Chen TH, et al. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. The American Journal of Physiology. 1995;269(6 Pt 1):E1095–E1100
  29. Kimura T, Makino Y, Saji F, et al. Molecular characterization of a cloned human oxytocin receptor. European Journal of Endocrinology. 1994;131(4):385–390
  30. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiological Reviews. 2001;81(2):629–683
  31. Young LJ, Wang Z, Insel TR. Neuroendocrine bases of monogamy. Trends in Neurosciences. 1998;21(2):71–75
  32. Insel TR, Winslow JT, Wang Z, et al. Oxytocin, vasopressin, and the neuroendocrine basis of pair bond formation. Advances in Experimental Medicine and Biology. 1998;449:215–224
  33. Sanborn BM, Dodge K, Monga M, et al. Molecular mechanisms regulating the effects of oxytocin on myometrial intracellular calcium. Advances in Experimental Medicine and Biology. 1998;449:277–286
  34. Soloff MS, Sweet P. Oxytocin inhibition of (Ca2+ + Mg2+)-ATPase activity in rat myometrial plasma membranes. The Journal of Biological Chemistry. 1982;257(18):10687–10693
  35. Gutkowska J, Jankowski M, Lambert C, et al. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(21):11704–11709
  36. Abbracchio MP, Burnstock G, Boeynaems JM, et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacolical Reviews. 2006;58(3):281–341
  37. Boarder MR, Weisman GA, Turner JT, et al. G protein-coupled P2 purinoceptors: from molecular biology to functional responses. Trends in Pharmacological Sciences. 1995;16(4):133–139
  38. Mei Q, Liang BT. P2 purinergic receptor activation enhances cardiac contractility in isolated rat and mouse hearts. American Journal of Physiology. Heart and Circulatory Physiology. 2001;281(1):H334–H341
  39. Zenteno-Savin T, Sada-Ovalle I, Ceballos G, et al. Effects of arginine vasopressin in the heart are mediated by specific intravascular endothelial receptors. European Journal Pharmacology. 2000;410(1):15–23
  40. Escorsell A, Ruiz del Arbol L, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (Baltimore, Md.). 2000;32(3):471–476
  41. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95(5):1122–1125
  42. Wenzel V, Krismer AC, Arntz HR, et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. The New England Journal of Medicine. 2004;350(2):105–113
  43. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. [review] [162 refs] Shock (Augusta, Ga.). 1996;6:79–88
  44. Asfar P, Hauser B, Ivanyi Z, et al. Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Critical Care Medicine. 2005;33(2):373–380
  45. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. The New England Journal of Medicine. 2001;345(8):588–595
  46. Asfar P, Hauser B, Radermacher P, et al. Catecholamines and vasopressin during critical illness. Critical Care Medicine. 2006;22(1):131–149vii–viii
  47. Martikainen TJ, Tenhunen JJ, Uusaro A, et al. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesthesia and Analgesia. 2003;97(6):1756–1763
  48. Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Critical Care Medicine. 2003;31(1):215–220
  49. Sun Q, Dimopoulos G, Nguyen DN, et al. Low-dose vasopressin in the treatment of septic shock in sheep. American Journal of Respiratory and Critical Care Medicine. 2003;168(4):481–486
  50. Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. Journal of Thrombosis and Haemostasis: JTH. 2003;1(4):821–828
  51. Bernat A, Hoffmann P, Dumas A, et al. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. The Journal of Pharmacology and Experimental Therapeutics. 1997;282(2):597–602

PII: S1521-6896(08)00027-X

doi: 10.1016/j.bpa.2008.03.003

Best Practice & Research Clinical Anaesthesiology
Volume 22, Issue 2 , Pages 253-263 , June 2008

Article Tools

* Image Usage & Resolution